Wall Street Zen Upgrades Gyre Therapeutics (NASDAQ:GYRE) to "Hold"

Gyre Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen upgraded Gyre Therapeutics from “sell” to “hold,” while Zacks Research also moved to “hold.” Weiss Ratings maintained a sell rating, leaving MarketBeat’s consensus at “Reduce.”
  • Gyre reported quarterly EPS of $0.04, beating the consensus estimate of a $0.15 loss, and revenue of $32.93 million versus estimates of $28.40 million.
  • Shares opened at $4.76; the company’s 52-week trading range is $3.97 to $9.14.
  • Five stocks we like better than Gyre Therapeutics.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday, Wall Street Zen reports.

Several other research analysts also recently commented on GYRE. Zacks Research raised shares of Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Tuesday, October 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Gyre Therapeutics in a research report on Wednesday. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Reduce".

View Our Latest Analysis on Gyre Therapeutics

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock opened at $4.76 on Friday. The firm has a market cap of $530.79 million, a PE ratio of -23.80 and a beta of 2.14. Gyre Therapeutics has a 52-week low of $3.97 and a 52-week high of $9.14. The business's 50 day simple moving average is $6.51 and its 200 day simple moving average is $6.90.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its earnings results on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.19. Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%. The company had revenue of $32.93 million for the quarter, compared to analyst estimates of $28.40 million. As a group, equities research analysts predict that Gyre Therapeutics will post -0.61 EPS for the current year.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE acquired a new position in shares of Gyre Therapeutics during the 2nd quarter worth about $83,000. Deutsche Bank AG acquired a new stake in Gyre Therapeutics in the 2nd quarter valued at about $118,000. Dimensional Fund Advisors LP raised its stake in Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after purchasing an additional 14,365 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock worth $301,000 after buying an additional 1,941 shares during the period. Finally, SBI Securities Co. Ltd. boosted its holdings in Gyre Therapeutics by 1.8% in the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company's stock valued at $1,244,000 after acquiring an additional 2,967 shares during the last quarter. Institutional investors and hedge funds own 23.99% of the company's stock.

About Gyre Therapeutics

(Get Free Report)

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company's lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Gyre Therapeutics Right Now?

Before you consider Gyre Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.

While Gyre Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines